Health-System Specialty Pharmacy Outcomes Research Consortium

Introduction:

In 2017, the health outcomes and research team at Vanderbilt Specialty Pharmacy created a collaborative Consortium with the goal of fostering cross-site research opportunities, educational activities, and networking among health-system specialty pharmacies across the country. As of Spring 2022, the Consortium is composed of 46 health-system specialty pharmacies (HSSPs).

Mission:

Demonstrate the value of health-system specialty pharmacies through collaborative outcomes research.

consortium members posing for a group photo

Goals of the Consortium


Goal 1

Perform multisite research studies demonstrating the value of the HSSPs with stronger sample sizes

Goal 2

Share best practices and research resources among HSSPs to empower as many as possible to demonstrate their value through outcomes research

Goal 3

Align/standardize outcomes metrics collected and reported by health-system specialty pharmacies where possible

Completed and Ongoing Research Projects (As of Spring 2022):

Adherence to self-administered biologic disease-modifying antirheumatic drugs across health-system specialty pharmacies (https://doi.org/10.1093/ajhp/zxab342)
  • This large, multisite retrospective cohort study was the first to demonstrate adherence rates across several HSSPs and provided novel insights into rates and reasons for appropriate gaps in therapy
  • Across 20 participating sites, the median adherence rate (measured by proportion of days covered [PDC]) was 0.94 using data from 29,994 prescriptions and 3,530 patients.

 

Management of Patients with Multiple Sclerosis within Health-System Specialty Pharmacies: Actions and Outcomes
  • This multisite prospective cohort study will be the first to report adherence and outcomes in patients with MS across multiple health-system specialty pharmacies. Additionally, it will provide needed insight into health-system specialty pharmacy management of patients with MS.
  • Results from this study will be presented at national conferences throughout 2022.

 

Clinical Services Provided by Health-Systems Specialty Pharmacies: A Survey of Current Practice
  • The objective of this multi-phased survey is to aggregate data to demonstrate the benefits of a health-system specialty pharmacy (HSSP) by demonstrating the clinical services provided by HSSPs.
  • A review of literature describing the role and outcomes of HSSPs has been submitted for publication
  • The Consortium partnered with ASHP to disseminate a survey to HSSPs assessing currently provided clinical services; results pending

 

Safety Screening in Patients Initiating Biologic Specialty Medications
  • This prospective cohort study will evaluate the role HSSPs play in patients safely initiating self-administered biologic therapies.
  • Study design and execution are currently in process.

 

Safety Screening in Patients Initiating Biologic Specialty Medications
  • This prospective cohort study will evaluate the role HSSPs play in patients safely initiating self-administered biologic therapies.
  • Study design and execution are currently in process.

 

Use of Deutetrabenazine Above Food and Drug Administration Maximum Recommended Dose
  • This retrospective study will assess the safety and effectiveness of deutetrabenazine doses greater than the currently DFA-approved 28mg per day.
  • Study design and execution are currently in process.

Networking and Educational Events:

Journal Club and Hot Topic Roundtables

The Consortium hosts a monthly event that alternates between a journal club, wherein authors present results from an applicable study, and a hot topic roundtable on a specialty pharmacy topic of interest. Both events include a brief presentation followed by discussion between presenters and attendees.

Contact Us

If you or your site are interested in joining the Consortium, please click the email link below!